Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass. , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance
August 09, 2023 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023
July 10, 2023 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results
May 10, 2023 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors
April 27, 2023 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2023 Financial Results on May 10, 2023
April 10, 2023 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Applauds Findings from the Office of Inspector General
March 27, 2023 08:00 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. Reports Fourth Quarter 2022 and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance
March 01, 2023 16:02 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
March 01, 2023 16:01 ET
|
Organogenesis Holdings Inc.
CANTON, Mass. , March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023
February 09, 2023 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...